摘要: Irinotecan is a relatively new anticancer agent of interest for both its clinical activity and complex pharmacology. It prodrug, requiring activation by carboxylesterases to SN-38, an inhibitor topoisomerase I. Recent studies suggest that human carboxylesterase-2 the primary
aacrjournals.org参考文章(19)
Mark J. Ratain, Elora Gupta, Xiaolin Wang, Ahmad R. Safa, Pharmacokinetic Modulation of Irinotecan and Metabolites by Cyclosporin A Cancer Research. ,vol. 56, pp. 1309- 1314 ,(1996)
Laurent P. Rivory, Marc Vuilhorgne, Alain Commerçon, Susan M. Pond, Jacques Robert, Marie-Christine Haaz, Jean-François Riou, Serge Sable, Identification and Properties of a Major Plasma Metabolite of Irinotecan (CPT-11) Isolated from the Plasma of Patients Cancer Research. ,vol. 56, pp. 3689- 3694 ,(1996)
E Gupta, R Mick, J Ramirez, X Wang, T M Lestingi, E E Vokes, M J Ratain, Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. Journal of Clinical Oncology. ,vol. 15, pp. 1502- 1510 ,(1997) , 10.1200/JCO.1997.15.4.1502
W. F. Bosron, K. Lohrbach, Lin Li, R. Humerickhouse, M. E. Dolan, Characterization of CPT-11 Hydrolysis by Human Liver Carboxylesterase Isoforms hCE-1 and hCE-2 Cancer Research. ,vol. 60, pp. 1189- 1192 ,(2000)
Yuichi Sugiyama, Xiao-Yan Chu, Yukio Kato, Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats. Drug Metabolism and Disposition. ,vol. 27, pp. 440- 441 ,(1999)
Yuichi Sugiyama, Xiao-Yan Chu, Yukio Kato, Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Research. ,vol. 57, pp. 1934- 1938 ,(1997)
Clayton W. Naeve, Peter J. Houghton, Pamela J. Cheshire, Cynthia A. Pawlik, Mary K. Danks, Lois B. Richmond, Erik J. Krull, Philip M. Potter, Christopher L. Morton, Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clinical Cancer Research. ,vol. 5, pp. 917- 924 ,(1999)
E. Gupta, Xiaolin Wang, Jacqueline Ramirez, M. J. Ratain, Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital Cancer Chemotherapy and Pharmacology. ,vol. 39, pp. 440- 444 ,(1997) , 10.1007/S002800050595
A Kojima, N R Hackett, A Ohwada, R G Crystal, In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. Journal of Clinical Investigation. ,vol. 101, pp. 1789- 1796 ,(1998) , 10.1172/JCI119888
L Iyer, C D King, P F Whitington, M D Green, S K Roy, T R Tephly, B L Coffman, M J Ratain, Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. Journal of Clinical Investigation. ,vol. 101, pp. 847- 854 ,(1998) , 10.1172/JCI915